Kyverna Therapeutics Inc(KYTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.94 | Insider Own | 37.66% | Shs Outstand | 61.6M | Perf Week | -13.05% |
| Market Cap | 0.45B | Forward P/E | - | EPS next Y | -9.89% | Insider Trans | - | Shs Float | 38.5M | Perf Month | -9.81% |
| Enterprise Value | 0.28B | PEG | - | EPS next Q | -0.69 | Inst Own | 47.54% | Short Float | 21.93% | Perf Quarter | -7.75% |
| Income | -0.15B | P/S | - | EPS this Y | 24.14% | Inst Trans | 5.44% | Short Ratio | 8.53 | Perf Half Y | -17.22% |
| Sales | 0.00B | P/B | 2.7 | EPS next 5Y | 14.19% | ROA | -68.4% | Short Interest | 8.45M | Perf YTD | -22.77% |
| Book/sh | 2.69 | P/C | 2.25 | EPS past 3/5Y | -75.86% -56.27% | ROE | -87.24% | 52W High | -46.89% ($13.67) | Perf Year | 74.94% |
| Cash/sh | 3.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -77.47% | 52W Low | 92.06% ($3.78) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 20.07% | Gross Margin | - | Volatility(W/M) | 4.27% 5.99% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.06 | EPS Q/Q | 35.37% | Profit Margin | - | RSI (14) | 37.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.06 | Sales Q/Q | - | SMA20 | -12.58% ($8.3) | Beta | 2.04 | Target Price | $30.4 |
| Payout | - | Debt/Eq | 0.2 | Earnings | 2026/8/11 | SMA50 | -10.41% ($8.1) | Rel Volume | 0.76 | Prev Close | $7.35 |
| Employees | 130 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | 7.12% - | SMA200 | -13.87% ($8.43) | Avg Volume(3M) | 0.99M | Price | $7.26 |
| IPO | 2024/2/8 | Option/Short | Yes/Yes | Trades | 7556 | Volume | 751,314 | Change | -1.22% |
Company
KYTX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Kyverna Therapeutics (KYTX) is a U.S. clinical-stage biopharmaceutical company developing next-generation cell therapies to treat autoimmune diseases. Leveraging its proprietary Smart Cell platform technology, the company is expanding CAR-T cell therapy—previously used mainly for cancer treatment—into a wide range of autoimmune disease areas, including lupus nephritis and multiple sclerosis. With its lead pipeline candidate miv-cel (KYV-101) at the core, Kyverna is committed to advancing research aimed at overcoming treatment-resistant diseases.
Over the past 1 year, roughly in the middle
47% below its 1-year high.
KYTX has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 47.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SURI 0.02%
DWAS 0.00%
KOMP 0.00%
IWC 0.00%
FSEG 0.00%It ranks #4 in the industry
Based on market cap of $449M.
KYTX $449M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is KYTX?
KYTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KYTX?
The market cap of KYTX is approximately $449M, ranking 3,316 within its sector.
What is the 52-week high and low for KYTX?
KYTX has recorded a 52-week high of $13.67 and a low of $3.78.
